#checkpoint-inhibitors — Tuesday, July 21, 2026 (1 items)
| 0 | 💬 0 |
Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial.
(nature.com)
|
Nature Communications 2026-07-21 | #cancer #immunotherapy #clinical trial #checkpoint-inhibitors #amr |